Status:

COMPLETED

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

Lead Sponsor:

Novartis

Collaborating Sponsors:

Novartis Vaccines

Conditions:

Meningococcal Disease

Meningococcal Meningitis

Eligibility:

All Genders

12-23 years

Phase:

PHASE2

Brief Summary

The study was to evaluate the safety and and immune response of each of three lots of Novartis Meningococcal C Conjugate Vaccine (MenC-CRM Liquid) when administered to Healthy Toddlers.

Eligibility Criteria

Inclusion

  • Healthy 12 - 23 (inclusive) month-old male or female toddlers.
  • A parent/legal guardian was given written informed consent after the nature of the study has been explained.
  • Available for both the visits scheduled in the study.
  • In good health as determined by medical history, physical examination and clinical judgment of the investigator.

Exclusion

  • History of any meningococcal vaccine administration.
  • Previous known or suspected disease caused by N. meningitidis.
  • Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection or colonization.
  • History of severe allergic reaction after previous vaccinations, allergy to Latex, or hypersensitivity to any component of the vaccine.
  • Significant acute or chronic infection within the previous 7 days or axillary temperature ≥38.0°C within the previous 3 days.
  • Individuals who have received antibiotics within 6 days before vaccination.
  • Known or suspected autoimmune disease or impairment/alteration of the immune system resulting from (for example):
  • Receipt of any immunosuppressive therapy at any time since birth.
  • Receipt of any immunostimulants at any time since birth.
  • Receipt of any systemic corticosteroids or chronic use of inhaled high-potency corticosteroids since birth (use of topical corticosteroids administered in limited areas of the body \[for example, eczema on knees or face or elbows\] is allowed).
  • Immune deficiency disorder, or known HIV infection.
  • History of seizure, any progressive neurological disease or Guillain Barré Syndrome (exception: one self-limited non-medicated febrile seizure is acceptable).
  • Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
  • Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks.
  • Taken any antipyretic medication in the previous 6 hours.
  • Received any other vaccines within 30 days prior to enrollment or intent to receive any other vaccine during the study (Exception: Inactivated influenza vaccine may be administered up to 15 days prior to study immunization and no less than 15 days after study immunization).
  • Toddler's parent(s) or legal guardian(s) are not able to comprehend and to follow all required study procedures for the whole period of the study.
  • Participation in any clinical trial with another investigational product 30 days prior to first study visit or intent to participate in another clinical study during this study.
  • Family members or household members of site research staff.
  • History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
  • Any serious chronic or progressive disease according to judgment of the investigator (neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).

Key Trial Info

Start Date :

September 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2012

Estimated Enrollment :

992 Patients enrolled

Trial Details

Trial ID

NCT01434680

Start Date

September 1 2011

End Date

November 1 2012

Last Update

April 25 2017

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

NZOZ Bioscience Sp zoo

Ul Czerkaska, Bydgoszcz, Poland

2

Department Infection Disease ZOZ

Dept Infection Disease ZOZ, Debica, Poland

3

Centrum Medyczne Graniczna Sp zoo

Ul Graniczna 45, Katowice, Poland

4

NZOZ HIPOKRATES IIspzoo

Ul Strzelecka 2, Krakow, Poland